SciELO - Scientific Electronic Library Online

SciELO - Scientific Electronic Library Online

Referencias del artŪculo

KHOSRAVI SHAHI, P.; CASTILLO RUEDA, A. del  y  PEREZ MANGA, G.. Angiogénesis neoplásica. An. Med. Interna (Madrid) [online]. 2008, vol.25, n.7, pp.366-369. ISSN 0212-7199.

    1. Kerbel RS. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 2006; 312: 1171-5. [ Links ]

    2. Khosravi P. Angiogenesis y neoplasias. An Med Interna 2006; 23: 355-6. [ Links ]

    3. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273-86. [ Links ]

    4. Bergers G, Benjamín LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-10. [ Links ]

    5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76. [ Links ]

    6. Veikkola T, Karkkainen M, Claesson-Welsh L, et al. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res 2000; 60: 203-12. [ Links ]

    7. Harris AL. Hypoxia-a key regulatory factor in tumor growth. Nat Rev Cancer 2002; 2: 38-47. [ Links ]

    8. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-39. [ Links ]

    9. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003; 9: 677-84. [ Links ]

    10. Shim WS, Ho IA, Wong PE. Angiopoietin: a TIE(d) Balance in Tumor Angiogenesis. Mol Cancer Res 2007; 5: 655-65. [ Links ]

    11. Kumar R, Yoneda J, Bucana CD, et al. Regulation of distinct steps of angiogenesis by different angiogenic molecules. Int J Oncol 1998; 12: 749-57. [ Links ]

    12. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145-7. [ Links ]

    13. Kabbinavar F, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus 5FU/leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-705. [ Links ]

    14. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer. N Engl J Med 2004; 350: 2335-42. [ Links ]

    15. Sandler A, Gray R, Perry MC, et al. Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. N Engl J Med 2006; 355: 2542-50. [ Links ]

    16. Sakamoto KM. SU-11248 SUGEN. Curr Opin Investig Drugs 2004; 5: 1329-39. [ Links ]

    17. Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471-8. [ Links ]

    18. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-37. [ Links ]

    19. Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 13: 1367-73. [ Links ]

    20. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus Interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-24. [ Links ]

    21. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 2505-12. [ Links ]

    22. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma. N Engl J Med. 2007; 356: 125-34. [ Links ]